Evidence map›Paper›PMID 41424723›Full record

ArticlePeerJ2025

Diabetes and respiratory diseases as comorbid conditions in COVID-19 patients from Kazakhstan: a retrospective pilot study.

Karlygash Tazhibayeva, Zinat Abdrakhmanova, Ariel Shensa, Aizhan Raushanova, Assel Sadykova, Natalya Glushkova, Saltanat Mamyrbekova, Zhanar Zhagiparova, Arailym Beisbekova, Faina Linkov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Karlygash Tazhibayeva *Al-Farabi Kazakh National University, Almaty, Kazakhstan.
Zinat Abdrakhmanova *Al-Farabi Kazakh National University, Almaty, Kazakhstan.
Ariel ShensaDuquesne University, Pittsburgh, PA, United States of America.
Aizhan RaushanovaAl-Farabi Kazakh National University, Almaty, Kazakhstan.
Assel SadykovaAl-Farabi Kazakh National University, Almaty, Kazakhstan.
Natalya GlushkovaAl-Farabi Kazakh National University, Almaty, Kazakhstan.
Saltanat MamyrbekovaKazakh National Medical University Named After S. D. Asfendiyarov, Almaty, Kazakhstan.
Zhanar ZhagiparovaAl-Farabi Kazakh National University, Almaty, Kazakhstan.
Arailym BeisbekovaKazakh National Medical University Named After S. D. Asfendiyarov, Almaty, Kazakhstan.
Faina LinkovDuquesne University, Pittsburgh, PA, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetes and respiratory diseases are prevalent in Central Asia, and their prevention represents an opportunity to increase life expectancy in the region, especially in Kazakhstan. This study aims to analyze trends in the prevalence of diabetes and respiratory diseases as comorbidities in patients with recent COVID-19 infections, based on the information obtained from several clinics in Almaty, Kazakhstan. Methods: This study was conducted as a cross-sectional analysis using de-identified electronic medical records from a multidisciplinary hospital in Almaty, Kazakhstan. Adults hospitalized with laboratory-confirmed COVID-19 during 2021-2022 were included ( Results: The mortality rate was higher among patients with pneumonia (16.8%) compared to chronic bronchitis (10.6%). We identified a high level of comorbidity with diabetes (35.3% in the 45-59 age group) and chronic respiratory disease (37.9% in the same group). Discussion: The mortality and comorbidity rates for hospitalized patients with recent COVID-19 infections in Almaty were high in comparison to other middle-income countries. These findings underscore the need for targeted early prevention strategies and public health interventions to address the rising burden of chronic diseases in Kazakhstan, particularly among middle-aged adults.

Indexed as

COVID-19Diabetes MellitusAdolescentAdultAgedAged, 80 and overComorbidityCross-Sectional StudiesFemaleHumansKazakhstanMaleMiddle AgedPilot ProjectsPrevalenceRetrospective StudiesCentral AsiaDiabetesDisease burdenKazakhstanPrevention

Identifiers

PMID41424723
PMCPMC12716145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.